Overview

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine